Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

NHSA of China adds generic lecanemab in its commercial insurance innovative drug list to treat early Alzheimer’s disease: Tokyo Thursday, December 11, 2025, 16:00 Hrs [IST] Toky ...

A new study published in Addiction has identified genetic factors that influence both a person’s risk of developing an addiction and their educational attainment. Researchers found that some genetic ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...